THOUSAND OAKS, Calif.,
Sept. 14, 2021 /PRNewswire/ --
Amgen (NASDAQ: AMGN) and The Lundquist Institute today
announced that Diadem Biotherapeutics, Inc., has been awarded the
first Amgen Golden Ticket in Southern
California. Diadem will receive one year of lab space at
BioLabs LA at The Lundquist Institute (TLI) as well as additional
facility benefits and connections to Amgen's scientific and
business leaders.
The 2021 Amgen Golden Ticket winner was chosen by an internal
team of Amgen scientific leaders at a virtual pitch event. Five
finalists pitched their business plans before Amgen's internal
committee that evaluated the strength and novelty of their
scientific rationale, subject matter expertise and business plan
viability. This is the first of three Amgen Golden Tickets to
be awarded over the next three years to help accelerate life
science start-ups in Southern
California.
Perspectives on announcement:
- "Amgen's partnership with BioLabs LA at The Lundquist Institute
(TLI) recognizes the rapid growth of bioscience innovation in the
Los Angeles area and aligns with
our aspiration to bring breakthrough therapies for patients. We are
enthusiastic about the exosome technology that is being advanced by
Diadem Biosciences, and look forward to engaging with the team as
they advance novel immunotherapies to treat serious illness" –
Philip Tagari, Ph.D., vice president
of Therapeutic Discovery at Amgen
- "Biolabs LA at the Lundquist Institute is honored to be working
with Amgen, a worldwide pioneer in biotechnology, to help identify
and support innovative up and coming life-science companies in
Southern California. Amgen's
three-year Golden Ticket sponsorship provides a unique opportunity
for BioLabs to help promote growth for startup companies in the
rapidly developing Los Angeles
market while relying on expert mentorship from Amgen, as the
premier industry partner in the region. Amgen serves as a model and
guidepost to encourage and champion companies to grow with local
resources being a key to their success. We look forward to having
Diadem join the BioLabs LA community and in assisting them, along
with Amgen and The Lundquist Institute, in reaching their
milestones. Together we will drive progress in the field of human
biology and patient health." – Lindsay
Bourgeois, director of BioLabs LA at the Lundquist
Institute
- "We are honored to have our approach to therapeutic signaling
endorsed by an expert judging panel of Amgen's leading scientists.
With the extensive resources at BioLabs LA and access to Amgen
expertise we can accelerate the development of a new class of
therapeutics that has the potential to enhance patient-care
outcomes across a range of diseases. That BioLabs LA is now at full
capacity speaks to the ambition of biotech startups in Los Angeles, and the fertile ground of this
ecosystem." – Mickey Pentecost,
Ph.D., co-founder and chief executive officer, Diadem
Biotherapeutics, Inc.
Amgen supports life science start-ups through Golden Ticket
awards and affiliated engagement in other Biotech Innovative hubs,
including San Francisco,
Boston and Toronto.
About Diadem Biotherapeutics, Inc.
Diadem Biotherapeutics, Inc. is a platform therapeutics
company developing a broad pipeline of first-in-class
immunotherapies. Leveraging expertise in genetic engineering and
scalable bioprocessing, Diadem is developing cell secreted
nanovesicles precisely engineered to deliver signals that mimic
natural cell-to-cell signaling. Diadem's unique approach enables
precise modulation of targets that play a role in chronic
inflammation, autoimmune diseases and immune control of cancers,
addressing some critical unmet clinical needs. For more
information, visit www.diadembio.com.
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential. For more information, visit
www.amgen.com and follow us on www.twitter.com/amgen.
About The Lundquist Institute: Research with reach™
The Lundquist Institute is an engine of innovation with a global
reach and a 69-year reputation of improving and saving lives. With
its new medical research building, its state-of-the-art incubator,
"BioLabs at The Lundquist," existing laboratory and support
infrastructure, and the development of a new 15-acre
business tech park, the Lundquist Institute serves as a hub
for the Los Angeles area's
burgeoning biotech scene. The research institute has over 100
principal investigators (Ph.D.s, M.D.s, and M.D./Ph.D.s) working on
more than 600 research studies, including therapies for numerous,
and often fatal orphan diseases. Find out more at
https://lundquist.org.
About BioLabs LA at The Lundquist Institute
Encompassing the entire third floor of The Lundquist Institute's
new Medical Research Lab building, BioLabs LA offers shared lab
facilities designed for high-potential, early-stage life since
companies. BioLabs creates co-working communities that pair
premium, fully equipped and supported lab and office space with
unparalleled access for entrepreneurs to networking, industry
partners, and capital. Find out more
at https://www.biolabs.io/la.
CONTACT:
Amgen
Michael Strapazon, 805-313-5553
(media)
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA
Medical Center
Keith B. Hoffman, Ph.D., (310)
974-9301, keith.hoffman@lundquist.org
BioLabs LA
Lindsay Bourgeois, (978) 852-1081,
lbourgeois@biolabs.io
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amgen-and-the-lundquist-institute-announce-that-diadem-therapeuctics-will-receive-the-first-amgen-golden-ticket-to-biolabs-la-301376747.html
SOURCE Amgen